← Back to Search

Imaging

Screening Methods for Liver Cancer

N/A
Waitlist Available
Led By Jessica P Hwang
Research Sponsored by M.D. Anderson Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Must be at least 18 years old
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 3 months
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing a new way to screen for liver fibrosis and cirrhosis. It may help improve survival for patients with liver cancer.

Who is the study for?
This trial is for adults over 18 who can speak and read English or another language with available translation at the HOPE clinic. It's open to new or current patients seeking regular care at the clinic, but pregnant individuals cannot participate.
What is being tested?
The study is testing how well surveys, blood tests, and a liver scan called Fibroscan can screen for liver fibrosis and cirrhosis in patients. The goal is to find better ways to detect liver cancer early on in people getting care at the HOPE clinic.
What are the potential side effects?
There are minimal side effects expected from this trial as it involves non-invasive procedures like surveys, blood tests, and Fibroscan (similar to an ultrasound). However, some discomfort may occur during blood collection.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am 18 years old or older.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 3 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 3 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Positive hepatitis B surface antigen test result
Secondary study objectives
Fibroscan result >= F2
Positive anti-hepatitis C virus (HCV) test result

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Screening (survey, biomarker analysis, fibroscan)Experimental Treatment4 Interventions
Patients complete surveys over 10-15 minutes, and undergo blood testing, clinical evaluation, and fibroscan at baseline.

Find a Location

Who is running the clinical trial?

M.D. Anderson Cancer CenterLead Sponsor
3,066 Previous Clinical Trials
1,801,245 Total Patients Enrolled
22 Trials studying Liver Cancer
9,398 Patients Enrolled for Liver Cancer
Cancer Prevention Research Institute of TexasOTHER
53 Previous Clinical Trials
98,044 Total Patients Enrolled
2 Trials studying Liver Cancer
68 Patients Enrolled for Liver Cancer
Jessica P HwangPrincipal InvestigatorM.D. Anderson Cancer Center
3 Previous Clinical Trials
2,258 Total Patients Enrolled

Media Library

Liver Ultrasonographic Elastography (Imaging) Clinical Trial Eligibility Overview. Trial Name: NCT04785534 — N/A
Liver Cancer Research Study Groups: Screening (survey, biomarker analysis, fibroscan)
Liver Cancer Clinical Trial 2023: Liver Ultrasonographic Elastography Highlights & Side Effects. Trial Name: NCT04785534 — N/A
~309 spots leftby Aug 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top